Table 3.
Univariate and multivariate analyses for overall survival in 135 LA-HNSCC patients receiving IC
| Characteristic | Univariate | Multivariate | ||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age (yr) | ||||
|
| ||||
| > 60 vs. ≤ 60 | 0.63 (0.32–1.23) | 0.175 | - | - |
|
| ||||
| Sex | ||||
|
| ||||
| Male vs. Female | 1.37 (0.48–3.88) | 0.554 | - | - |
|
| ||||
| ECOG PS | ||||
|
| ||||
| 2 vs. 0–1 | 2.05 (0.62–6.71) | 0.237 | - | - |
|
| ||||
| Smoking history | ||||
|
| ||||
| Current or former vs. never | 1.12 (0.43–2.96) | 0.812 | - | - |
|
| ||||
| Alcohol history | ||||
|
| ||||
| Drink vs. do not drink | 2.38 (0.73–7.74) | 0.150 | - | - |
|
| ||||
| Primary tumor location | ||||
|
| ||||
| Oropharynx | 1 (reference) | 1 (reference) | ||
|
| ||||
| Oral cavity | 4.38 (1.75–10.92) | 0.002 | 3.13 (1.37–7.19) | 0.007 |
|
| ||||
| Hypopharynx | 2.11 (0.85–5.26) | 0.108 | - | - |
|
| ||||
| Larynx | 2.69 (0.93–7.75) | 0.067 | - | - |
|
| ||||
| Others | 1.77 (0.49–6.36) | 0.379 | - | - |
|
| ||||
| T classification | 1.90 (1.31–2.77) | 0.001 | 1.71 (1.14–2.58) | 0.010 |
|
| ||||
| N classification | 1.35 (0.76–2.39) | 0.307 | 1.93 (1.09–3.42) | 0.024 |
|
| ||||
| p16/HPV status | ||||
|
| ||||
| Negative | 1 (reference) | |||
|
| ||||
| Positive | 0.71 (0.31–1.64) | 0.425 | - | - |
|
| ||||
| IC regimen | ||||
|
| ||||
| Fluorouracil+cisplatin | 1 (reference) | |||
|
| ||||
| Docetaxel+cisplatin | 0.51 (0.21–1.21) | 0.128 | - | - |
|
| ||||
| Docetaxel+cisplatin+fluorouracil | 0.65 (0.26–1.59) | 0.066 | - | - |
|
| ||||
| Others | 0.14 (0.02–1.14) | 0.344 | - | - |
|
| ||||
| IC-guided treatment | ||||
|
| ||||
| IC responder+CCRT | 1 (reference) | 1 (reference) | ||
|
| ||||
| IC responder+surgery | 1.03 (0.30–3.60) | 0.960 | - | - |
|
| ||||
| IC non-responder+CCRT | 5.54 (2.43–12.64) | < 0.001 | 4.49 (1.84–10.93) | 0.001 |
|
| ||||
| C non-responder+surgery | 3.75 (1.57–8.94) | 0.003 | 2.60 (1.09–6.20) | 0.030 |
CCRT, concurrent chemoradiotherapy; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus; HR, hazard ratio; IC, induction chemotherapy; LA-HNSCC, locally advanced head and neck squamous cell carcinoma.